Vitamin D(3) and methylenebisphosphonic acid in the correction of mineral metabolism disorders and bone remodeling associated with glucocorticoid-induced osteoporosis

The study was aimed at evaluating therapeutic efficacy of vitamin D3 (VD3, 1000 IU/kg of b.w., 30 days) and sodium salt of methylenebisphosphonic acid (MBPA, 17 mg/kg of b.w., 30 days) monotherapies as well as their effect in combination in preventing mineral metabolism and bone remodeling disturbances associated with glucocorticoid(GC)-induced osteoporosis. Osteoporosis in rats was induced by long-term (30 days) administration of the synthetic glucocorticoid prednisolone (5 mg/kg of b.w.). Calcium and inorganic phosphate levels, activity of alkaline phosphatase (ALP) in serum, bone tissue and bone marrow were determined spectrophotometrically. The protein levels of VD3 receptor (VDR), receptor activator of nuclear factor kappa-B (RANK), its ligand (RANKL), and osteoprotegerin (OPG) in bone tissue were determined by Western blotting. Serum 25-hydroxyvitamin D3 (25OHD3) content was assayed by ELISA. It was shown that prednisolone caused the development of hypocalcemia and hypophosphatemia, increased the alkaline phosphatase activity in the blood serum, while downregulating its activity in bone tissue and bone marrow. GC-induced osteoporosis was accompanied by a profound deficiency of VD3 and a decrease in the content of VDR. Evaluation of the NF-κB-associated cytokine axis RANK/RANKL/OPG, which regulates the balance of osteoblasts/osteoclasts, showed a simultaneous decrease in the RANK content and OPG/RANKL ratio. Vitamin D3 restored mineral metabolism and 25OHD3 level that led to the normalization of VDR-mediated signaling­ and RANK/RANKL/OPG functions in bone tissue. It has been shown that the administration of MBPA had a corrective effect on the content of mineral components in the blood serum and bone tissue, as well as on the activity­ of alkaline phosphatase only in combination with vitamin D3, indicating a low efficiency of bisphosphonate monotherapy in GC-induced vitamin D3 deficiency and osteoporosis. Keywords: bone remode­ling, glucocorticoid-induced osteoporosis, methylenebisphosphonic acid, RANK/RANKL/OPG axis, vitamin D3

[1]  J. Fleet.  Vitamin D-Mediated Regulation of Intestinal Calcium Absorption , 2022, Nutrients.

[2]  Xiaoxia Zhou,et al.  Naringenin is a Potential Anabolic Treatment for Bone Loss by Modulating Osteogenesis, Osteoclastogenesis, and Macrophage Polarization , 2022, Frontiers in Pharmacology.

[3]  R. T. Alexander,et al.  Regulation of 1 and 24 hydroxylation of vitamin D metabolites in the proximal tubule , 2022, Experimental biology and medicine.

[4]  D. Bugarski,et al.  Vitamin D3 Stimulates Proliferation Capacity, Expression of Pluripotency Markers, and Osteogenesis of Human Bone Marrow Mesenchymal Stromal/Stem Cells, Partly through SIRT1 Signaling , 2022, Biomolecules.

[5]  R. Trivedi,et al.  Benzofuran pyran hybrid prevents glucocorticoid induced osteoporosis in mice via modulation of canonical Wnt/β-catenin signaling , 2022, Apoptosis : an international journal on programmed cell death.

[6]  Kuo-Hu Chen,et al.  Osteoporosis Due to Hormone Imbalance: An Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover , 2022, International journal of molecular sciences.

[7]  Xiaolin Huang,et al.  Zoledronic acid inhibits osteoclastogenesis and bone resorptive function by suppressing RANKL-mediated NF-κB and JNK and their downstream signalling pathways , 2021, Molecular Medicine Reports.

[8]  N. Hatch,et al.  Tissue Nonspecific Alkaline Phosphatase Function in Bone and Muscle Progenitor Cells: Control of Mitochondrial Respiration and ATP Production , 2021, International journal of molecular sciences.

[9]  O. Lisakovska,et al.  Vitamin D Auto-/Paracrine System Is Involved in Modulation of Glucocorticoid-Induced Changes in Angiogenesis/Bone Remodeling Coupling , 2020, International journal of endocrinology.

[10]  Heidi Ledford.  Coronavirus breakthrough: dexamethasone is first drug shown to save lives , 2020, Nature.

[11]  S. Vimalraj.  Alkaline Phosphatase: Structure, Expression and its Function in Bone Mineralization. , 2020, Gene.

[12]  D. Fang,et al.  Investigation of bone matrix composition, architecture and mechanical properties reflect structure-function relationship of cortical bone in glucocorticoid induced osteoporosis. , 2020, Bone.

[13]  D. Bikle.  Vitamin D: Newer Concepts of Its Metabolism and Function at the Basic and Clinical Level , 2020, Journal of the Endocrine Society.

[14]  R. Bouillon,et al.  Vitamin D Binding Protein: A Historic Overview , 2020, Frontiers in Endocrinology.

[15]  T. O. Veklich,et al.  Pathways and mechanisms of transmembrane calcium ions exchange in the cell nucleus , 2018, The Ukrainian Biochemical Journal.

[16]  V. Yukalo,et al.  Isolation of κ-CN-1P and Β-CN-5Р fractions from native casein micelles , 2018, The Ukrainian Biochemical Journal.

[17]  O. Lisakovska,et al.  Vitamin D3 Modulates Impaired Crosstalk Between RANK and Glucocorticoid Receptor Signaling in Bone Marrow Cells After Chronic Prednisolone Administration , 2018, Front. Endocrinol..

[18]  O. Lisakovska,et al.  Effects of Cholecalciferol on Key Components of Vitamin D-Endo/Para/Autocrine System in Experimental Type 1 Diabetes , 2018, International journal of endocrinology.

[19]  V. Pekhnyo,et al.  EFFECASY OF BISPHOSPHONIC ACIDS IN FEMALE RATS WITH EXPERIMENTAL OSTEOPOROSIS , 2017 .

[20]  J. Puzas,et al.  Sclerostin activity plays a key role in the negative effect of glucocorticoid signaling on osteoblast function in mice , 2017, Bone Research.

[21]  O. Lisakovska,et al.  Vitamin D3 protects against prednisolone-induced liver injury associated with the impairment of the hepatic NF-κB/iNOS/NO pathway. , 2017, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[22]  T. Komori,et al.  Glucocorticoid Signaling and Bone Biology , 2016, Hormone and Metabolic Research.

[23]  Cameron P. Brown,et al.  Vitamin D receptor expression in human bone tissue and dose-dependent activation in resorbing osteoclasts , 2016, Bone Research.

[24]  M. Oray,et al.  Long-term side effects of glucocorticoids , 2016, Expert opinion on drug safety.

[25]  J. Millán,et al.  Alkaline Phosphatase and Hypophosphatasia , 2015, Calcified Tissue International.

[26]  W. Liu,et al.  Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review). , 2015, Molecular medicine reports.

[27]  Apukhovskaia Li,et al.  [The ROS-generating and antioxidant systems in the liver of rats treated with prednisolone and vitamin D3]. , 2014 .

[28]  R. Russell,et al.  Bisphosphonates: the first 40 years. , 2011, Bone.

[29]  J. Mönkkönen,et al.  Biochemical and molecular mechanisms of action of bisphosphonates. , 2011, Bone.

[30]  J. David,et al.  Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. , 2010, Cell metabolism.

[31]  G. Ioannidis,et al.  Glucocorticoid-induced osteoporosis , 2000, Expert review of endocrinology & metabolism.

[32]  S. Bessman,et al.  A rapid nonenzymatic assay for 2,3-DPG in multiple specimens of blood. , 1973, Archives of environmental health.

[33]  P. Dhawan,et al.  Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. , 2016, Physiological reviews.